➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
Merck
Moodys
McKesson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SUTENT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Sutent

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00137436 ↗ Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer Completed Pfizer Phase 1/Phase 2 2005-10-01 This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
NCT00246571 ↗ Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed Pfizer Phase 2 2006-01-01 The purpose of this study is to compare progression free survival for SU011248 [sutent (sunitinib malate)] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast cancer.
NCT00265317 ↗ A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone Completed Pfizer Phase 2 2006-06-01 This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sutent

Condition Name

Condition Name for Sutent
Intervention Trials
Renal Cell Carcinoma 16
Metastatic Renal Cell Carcinoma 12
Carcinoma, Renal Cell 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sutent
Intervention Trials
Carcinoma, Renal Cell 56
Carcinoma 50
Kidney Neoplasms 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sutent

Trials by Country

Trials by Country for Sutent
Location Trials
United States 419
Canada 56
Japan 39
Italy 37
Germany 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sutent
Location Trials
Texas 31
California 21
Ohio 19
New York 19
Florida 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sutent

Clinical Trial Phase

Clinical Trial Phase for Sutent
Clinical Trial Phase Trials
Phase 4 3
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sutent
Clinical Trial Phase Trials
Completed 66
Terminated 21
Recruiting 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sutent

Sponsor Name

Sponsor Name for Sutent
Sponsor Trials
Pfizer 77
M.D. Anderson Cancer Center 11
National Cancer Institute (NCI) 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sutent
Sponsor Trials
Other 136
Industry 128
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Johnson and Johnson
Baxter
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.